TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37948006
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg ODT q.o.d.
Study: 37948170
Drug: PRISCA (patient-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRISCA (patient-centered approach including healthy lifestyle promotion, pharmacological management of CVRFs, psychotropic drug optimization, and motivational follow-up)
Study: 37948736
Drug: Inhaled Molgramostim
Normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Molgramostim
Study: 37948759
Drug: Neutralizing monoclonal
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing monoclonal antibodies (nmAbs)
Study: 37948832
Drug: KW-6356 3
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-6356 3 mg/day
Study: 37948832
Drug: KW-6356 6
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-6356 6 mg/day
Study: 37949617
Drug: TIL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL treatment during chemotherapy without IFNa (n=13)
Study: 37949617
Drug: TIL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL treatment with IFNa
Study: 37949617
Drug: TIL infusions
Normalized name: CD8 enriched young TIL
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL infusions during platinum-based chemotherapy
Study: 37949619
Drug: Obstetrics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetrics and gynaecology (O&G) trainees
Study: 37949619
Drug: Senior obstetrics
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senior obstetrics and gynaecology (O&G) trainees
Study: 37949621
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg oral daily
Study: 37949730
Drug: Higher radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher radiation dose (37.5-40 Gy)
Study: 37949730
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses (32.5 to 40 Gy)
Study: 37949730
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose levels
Study: 37950144
Drug: Etripamil (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etripamil (70 mg)
Study: 37950338
Drug: Amcenestrant 400
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcenestrant 400 mg
Study: 37950338
Drug: Amcenestrant 200
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcenestrant 200 mg
Study: 37950370
Drug: Cerebrolysin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin therapy
Study: 37950392
Drug: Asundexian (10/20/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asundexian (10/20/50 mg daily)
Study: 37950392
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard antiplatelet treatment
Study: 37950533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 8-type HPV genotype restriction and VIA
Study: 37950726
Drug: Etripamil nasal
Normalized name: etripamil
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etripamil nasal spray 70 mg
Study: 37950897
Drug: Aspirin avoidance
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin avoidance
Study: 37950907
Drug: Self-monitoring with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring with research physician-optimized antihypertensive titration
Study: 37950918
Drug: High-sodium diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium diet (approximately 2200 mg sodium added daily to usual diet)
Study: 37950918
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (approximately 500 mg daily total)
Study: 37950919
Drug: Self-monitoring along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring along with physician-optimized antihypertensive titration
Study: 37951069
Drug: Self-management program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management program based on acceptance and commitment therapy
Study: 37951218
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy combined with toripalimab
Study: 37951245
Drug: Orismilast 20
Normalized name: Orismilast
DrugBank: Orismilast (DB19042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orismilast 20 mg
Study: 37951245
Drug: Orismilast 30
Normalized name: Orismilast
DrugBank: Orismilast (DB19042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orismilast 30 mg
Study: 37951292
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg plus Ezetimibe 10 mg (combination lipid-lowering therapy)
Study: 37951292
Drug: High-intensity atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity atorvastatin monotherapy
Study: 37951560
Drug: Standard vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard vedolizumab (300 mg every 8 weeks)
Study: 37951560
Drug: Dose-optimized vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-optimized vedolizumab (600 mg at week 6, then 300 mg every 4 weeks or 600 mg at week 6, then 600 mg every 4 weeks)
Study: 37951560
Drug: Dose-optimized vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-optimized vedolizumab
Study: 37951954
Drug: Dostarlimab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (500 mg)
Study: 37952114
Drug: NX-13 250
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-13 250 mg immediate release (IR)
Study: 37952114
Drug: NX-13 500
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-13 500 mg immediate release (IR)
Study: 37952114
Drug: NX-13 500
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-13 500 mg delayed release (DR)
Study: 37952114
Drug: NX-13 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-13 (all doses)
Study: 37952131
Drug: Semaglutide (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (2.4 mg, once-weekly subcutaneous)
Study: 37952132
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg twice daily (2.5 mg twice daily when indicated)
Study: 37952133
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin cutoff for transfusion, 7 or 8 g per deciliter)
Study: 37952133
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin cutoff, <10 g per deciliter)
Study: 37952254
Drug: lepodisiran 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: lepodisiran 4 mg
Study: 37952254
Drug: lepodisiran 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: lepodisiran 12 mg
Study: 37952254
Drug: lepodisiran 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: lepodisiran 32 mg
Study: 37952254
Drug: lepodisiran 96
Approvals — FDA: no, EMA: no, PMDA: no
Description: lepodisiran 96 mg
Study: 37952254
Drug: lepodisiran 304
Approvals — FDA: no, EMA: no, PMDA: no
Description: lepodisiran 304 mg
Study: 37952254
Drug: lepodisiran 608
Approvals — FDA: no, EMA: no, PMDA: no
Description: lepodisiran 608 mg
Study: 37952548
Drug: Discontinuous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinuous oxytocin (infusion stopped beyond 6 cm dilation)
Study: 37952548
Drug: Continuous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous oxytocin (administration continued until delivery)
Study: 37952550
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir disoproxil fumarate plus emtricitabine
Study: 37952982
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine (Oral-AZA) maintenance
Study: 37952982
Drug: Injectable hypomethylating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable hypomethylating agents as first subsequent therapy (FST) after Oral-AZA
Study: 37952982
Drug: Injectable hypomethylating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable hypomethylating agents as first subsequent therapy (FST) after placebo
Study: 37953814
Drug: Duvelisib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvelisib (25 mg) for up to 10 days
Study: 37954037
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus platinum-based chemotherapy (arm A)
Study: 37954037
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus platinum-based chemotherapy (arm C)
Study: 37954906
Drug: Pegmolesatide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegmolesatide (administered once every four weeks)
Study: 37954906
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (administered one to three times per week)
Study: 37955005
Drug: Once-daily rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily rhGH
Study: 37955580
Drug: In utero
Normalized name: Uteroglobin
DrugBank: Uteroglobin (DB14880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In utero enzyme replacement therapy (IUERT)
Study: 37955580
Drug: Postnatal enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal enzyme replacement therapy (ERT)
Study: 37955644
Drug: Intensive Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Insulin Management
Study: 37955741
Drug: Fedratinib 400
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 400 mg orally as intact capsules with a nutritional supplement
Study: 37955741
Drug: Fedratinib contents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fedratinib contents dispersed in a nutritional supplement via nasogastric tube
Study: 37955741
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose of 200 mg orally twice daily as intact capsules with a nutritional supplement
Study: 37955745
Drug: Postnatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal steroids (betamethasone, hydrocortisone hemisuccinate)
Study: 37955745
Drug: No postnatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postnatal steroids (control group)
Study: 37955825
Drug: Sotrovimab 500
Normalized name: sotrovimab 500 MG in 8 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrovimab 500 mg IM dose
Study: 37956679
Drug: dupilumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: dupilumab (100 mg for those weighing ≤30 kg and 200 mg for those weighing more than 30 kg, administered once every 2 weeks by subcutaneous injection)
Study: 37956679
Drug: placebo (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (during VOYAGE) followed by dupilumab (100 or 200 mg, according to bodyweight, administered once every 2 weeks by subcutaneous injection)
Study: 37956738
Drug: Pemigatinib 13.5
Normalized name: pemigatinib 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemigatinib 13.5 mg once daily continuously (CD)
Study: 37956738
Drug: Pemigatinib 13.5
Normalized name: pemigatinib 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemigatinib 13.5 mg once daily intermittently (ID)
Study: 37956792
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence enhanced chronic disease care clinical decision support (eCDC-CDS) integrated within the electronic health record (EHR)
Study: 37956897
Drug: Warfarin (managed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (managed at INR goal of 2.0-2.5)
Study: 37956906
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic formula containing Bifidobacterium bifidum, B lactis, Lactobacillus acidophilus, L paracasei, L rhamnosus, and Streptococcus thermophilus, 2 capsules daily for 2 weeks
Study: 37956906
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 capsules daily for 2 weeks
Study: 37956906
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic formula
Study: 37956934
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen treatment (COT)
Study: 37956984
Drug: Tablet-based intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based intervention designed to improve decision-making with respect to health risk behaviors
Study: 37957175
Drug: Risk-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-directed therapy based on genetics and MRD
Study: 37957373
Drug: KT-474 (SAR444656)
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KT-474 (SAR444656) administered as a single dose and then daily for 14 days in healthy volunteers (105 total).
Study: 37957373
Drug: KT-474 (SAR444656)
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KT-474 (SAR444656) administered for 28 days in an open-label cohort of 21 patients.
Study: 37957378
Drug: Neoadjuvant immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immune checkpoint blockade (ICB) treatment
Study: 37957535
Drug: Mopati intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mopati intervention (treatment partner intervention)
Study: 37957689
Drug: HPV-DNA testing
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-DNA testing coupled with thermal ablation treatment
Study: 37957702
Drug: Praziquantel and
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel and Vitamin A on Day 0, followed by SMC drugs on Days 1-3 (treatment group 1)
Study: 37957702
Drug: Albendazole and
Normalized name: Albendazole and ivermectin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole and praziquantel on Day 0, followed by SMC drugs on Days 1-3 (treatment group 2)
Study: 37957702
Drug: SMC drugs
Normalized name: prosolv SMCC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC drugs only (control group)
Study: 37957702
Drug: Praziquantel and
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel and SMC drugs
Study: 37958331
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg lenalidomide maintenance therapy
Study: 37958331
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg lenalidomide maintenance therapy
Study: 37960292
Drug: Miraculin-based food
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miraculin-based food supplement
Study: 37960985
Drug: Sapanisertib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib (3 mg orally daily for 21 days every 28 days)
Study: 37961215
Drug: IL13BBζ-CAR T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles
Study: 37961683
Drug: Patient-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific treatment planning using measured optical properties
Study: 37962072
Drug: Nivolumab at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab at 3 mg/kg every 2 weeks
Study: 37962077
Drug: Elafibranor (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elafibranor (80 mg once daily)
Study: 37962202
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (OM Group)
Study: 37962746
Drug: bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bardoxolone methyl 5-15 mg/day (titrated as tolerated)
Study: 37962771
Drug: Combination frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination frequency ELF-EMF (5-16-40 Hz)
Study: 37962876
Drug: Oral health-related
Normalized name: Healthy Mama Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health-related quality of life measured with the Oral Health Impact Profile (OHIP) instrument
Study: 37963155
Drug: HemoCue 301
Approvals — FDA: no, EMA: no, PMDA: no
Description: HemoCue 301 with a cut-off of 11.1 g/dL
Study: 37963155
Drug: Automated Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Hb with a cut-off of 10.8 g/dL
Study: 37963723
Drug: Personalised EID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised EID with a target drug trough concentration of 10 µg/mL (EID10)
Study: 37963723
Drug: Personalised EID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised EID with a target drug trough concentration of 5 µg/mL (EID5)
Study: 37963723
Drug: Standard interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interval dosing (SID) of 4 weeks
Study: 37964096
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Assessment Tool (OHAT)
Study: 37964096
Drug: Functional Oral
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Oral Intake Scale (FOIS)
Study: 37964379
Drug: Cabiralizumab (anti-CSF1R),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist), and nivolumab (anti-PD-1)
Study: 37964379
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of anti-CSF1R in murine models
Study: 37964431
Drug: 3-mg nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-mg nicotine concentration ONP
Study: 37964431
Drug: 6-mg nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mg nicotine concentration ONP
Study: 37965250
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to the Holy Quran recital for 10 minutes twice daily
Study: 37965307
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of TMEscore with drug susceptibility and immune cell infiltration.
Study: 37965339
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell product specific for CMV and EBV, administered on day +30, total of 25 doses
Study: 37965376
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (n=17)
Study: 37965376
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n=16)
Study: 37965466
Drug: Photon-based radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon-based radiation therapy (XRT)
Study: 37965771
Drug: Low-dose epinephrine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epinephrine added to spinal anesthesia
Study: 37966877
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention 'Olitor' (app usage at least weekly for 3 months)
Study: 37967050
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy customized for visual symptoms (MBCT-vision)
Study: 37967058
Drug: Door-to-door delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Door-to-door delivery of oral azithromycin
Study: 37967058
Drug: Fixed-point delivery
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-point delivery of oral azithromycin
Study: 37967148
Drug: KCONVAC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCONVAC vaccine (2 doses, 28 days apart)
Study: 37967326
Drug: 1-dose rVSVΔG-ZEBOV-GP
Normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-dose rVSVΔG-ZEBOV-GP
Study: 37967326
Drug: 2-dose rVSVΔG-ZEBOV-GP
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose rVSVΔG-ZEBOV-GP (given on Day 0 and Day 56)
Study: 37968012
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole intravenously daily while mechanically ventilated in the ICU
Study: 37968012
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo daily while mechanically ventilated in the ICU
Study: 37968015
Drug: Mean pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean pulmonary artery pressure-cardiac output >5 mm Hg.min/L
Study: 37968019
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy involving early coronary angiography with immediate evaluation for revascularization and optimal medical therapy